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Background: The recent outbreak of Q fever in the Netherlands between 2007 and 2009 is the largest recorded Q
fever outbreak. Exposure to Coxiella burnetii may cause Q fever but the size of the population exposed during the
outbreak remained uncertain as little is known of the infectivity of this pathogen. The quantification of the
infectiousness and the corresponding response is necessary for assessing the risk to the population.
Methods: A human challenge study was published in the 1950s but this study quantified the dose of C. burnetii in
relative units. Data from a concurrent guinea pig challenge study were combined with a recent study in which
guinea pigs were challenged with a similar aerosol route to quantify human exposure. Concentration estimates for
C. burnetii are made jointly with estimates of the dose response parameters in a hierarchical Bayesian framework.
Results: The dose for 50% infection (InfD50%) in human subjects is 1.18 bacteria (95% credible interval (CI) 0.76-40.2).
The dose for 50% illness (IllD50) in challenged humans is 5.58 (95%CI 0.89-89.0) bacteria. The probability of a single
viable C. burnetii causing infection in humans is 0.44 (95%CI 0.044-0.59) and for illness 0.12 (95%CI 0.0006-0.55).
Conclusions: To our knowledge this is the first human dose–response model for C. burnetii. The estimated dose
response relation demonstrates high infectivity in humans. In many published papers the proportion of infected
individuals developing illness is reported to be 40%. Our model shows that the proportion of symptomatic infections
may vary with the exposure dose. This implies that presence of these bacteria in the environment, even in small
numbers, poses a serious health risk to the population.
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The Netherlands recently underwent the largest Q fever
outbreak on record with more than 3500 notified cases
between 2007 and 2009 [1] and possibly more than
40,000 infections [2] with a substantial disease burden
(Brooke et al., manuscript under consideration). The
outbreak was associated with an increase in intensive
goat farming and attributed to the release of bacteria
during multiple abortion storms in the region [3,4].
Mass culling and subsequent vaccination of goats halted
the outbreak but whether the effects of these measures
are permanent is still unknown as background incidence
remains above pre-outbreak levels [4].
In order to better understand the relation between hu-
man exposure to Coxiella burnetii released into the* Correspondence: J.Brooke@umcutrecht.nl
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reproduction in any medium, provided the orenvironment near infected goat farms, and the risk of
subsequent health effects, efforts are ongoing to quantify
the risk of becoming infected or developing acute symp-
toms given exposure to C. burnetti. A dose response
model describes the functional relationship between the
dose (the magnitude of exposure) and the probability of
infection and/or acute illness, allowing translation of ex-
posure estimates into risk estimates. Although dose re-
sponse relations have been published for several microbial
pathogens based upon human challenge studies, such in-
formation is normally not available for pathogens that can
cause severe illness, such as C. burnetii.
During the cold war in the 1950s and 1960s, the
United States military performed human challenge studies
for many biological agents that were deemed a plausible
biological weapon [5]. One of these studies [6] established a
dose response relationship in humans for C. burnetii. How-
ever, in this study the challenge dose was not expressed inLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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suspension in egg slurry. Concurrent to the human chal-
lenge experiment a guinea pig challenge experiment was
performed with the same methodology and materials. More
recently, Russell-Lodrigue et al. performed a similar experi-
ment on guinea pigs with a quantified dose of C. burnetii
expressed in numbers of bacteria [7]. In this paper we com-
bine these studies to estimate the infectious dose for the
human challenge study in numbers of bacteria and estab-
lish a human dose response model for C. burnetii.
Methods
Data
The original challenge studies by Tigertt et al. [6] used egg
slurry infected with the AD strain of C. burnetii, diluted
with water, aerosolized in an aerosol chamber of known
size to study the exposure-response relationship. Infection
was defined as seroconversion in a patient by standard
complement fixation 10 to 20 days after illness. In addition,
clinical symptoms were recorded for all patients. Clinical
symptoms of a typical infection included the onset of per-
sistent temperature above 38°C (100°F), lassitude, loss of
appetite, headache, mild photophobia, bradycardia, and oc-
casionally a palpable spleen. Chest radiography (x-ray)
showed evidence of pneumonia in roughly half of patients
developing clinical illness though no cough or rhonchi
were observed and the size of lesions were not related to
dose. The data used is taken from the original articles
(Table 1). The more recent challenge study in guinea pigs
[7] used bacterial challenge doses quantified by commer-
cially available bacterial viability kit (Live/Dead BacLight
bacterial viability kit Molecular Probes, Eugene, OR) ad-
ministered through a specialized apparatus to deliver aero-
sol uniformly within an exposure chamber [7,8].
When estimating the aerosol dose in the Tigertt study
the different respiratory rates of guinea pigs and humansTable 1 Datasets from original articles used to estimate dose
Tigertt guinea pig Tigertt huma
Egg slurry E I S Egg slurry E
10-6 29 0 - 10-6 2
10-5 26 1 - 10-5 5
10-4 24 4 - 10-4.5 3
10-3 27 22 - 10-4 8
10-2 28 28 - 10-3 5
10-1 24 24 - 10-2 4
10-1 2
*Two of the guinea pigs died before the end of the study when seroconversion wa
Egg slurry - dilutions of 1 milliliter of infected egg slurry with milliliters of sterile wa
Bacteria - a Poisson process exposure number of bacteria.
E - number of exposed per exposure group.
I - number of infected individuals per exposure group.
S - number of symptomatic per exposure group.need to be taken into account. The estimated dose is cal-
culated using the concentration of bacteria in the aero-
sol and the volume of aerosol inhaled during the one
minute period of exposure. Respiratory rates of infec-
tious aerosol were assumed to be a log-normal distrib-
uted; 5–10 l (geometric mean (GM) 7.1 l) for humans
[9] and 0.1-0.35 l (GM 0.19 l) for guinea pigs [10].
The Russell-Lodrigue et al. study uses particle counts
to determine the number of particles in the stock solution
after purifying the Nine Mile (RSA 493) strain. Serum sam-
ples were tested by ELISA and clinical signs recorded
under direct observation during the study period. Clinical
signs, such as increased respiratory rates and sounds were
recorded as well as fever and histopathological changes to
relevant organs.
Model
The dose response relation used to predict infection is a
hit theory model that assumes Poisson exposure and a
variable (beta distributed) probability of a pathogen sur-
viving all host barriers to infection [11]. Poisson distrib-
uted exposure implies that the inhalation of a volume V
from a suspension of concentration c results in exposure
to a discrete random number of bacteria that is Poisson
distributed with an expected value of cV. Heterogeneity
in the host-pathogen interaction is taken into account by
assuming that the variable probability of any individual
infectious particle succeeding in surviving all host bar-
riers and causing infection, is beta distributed [11]. The
resulting dose response relation is
P inf cV α; βÞ ¼ 1−1F1 α; αþ β; cVð Þjð
where 1F1() is a confluent hypergeometric function [12]
and (α,β) are the parameters of the beta distribution
describing heterogeneity. Infection may not always beresponse relationships
n Russell-Lodrigue guinea pig
I S Bacteria E I S
0 0 2 x 101 3 3 2
4 2 2 x 102 3 3 3
3 3 2 x 103 3 3 3
7 7 2 x 104 3 3 3
4 4 2 x 105 3 3 3




Table 2 Parameter estimates for infection and illness
dose response of posterior MC estimates
α β
Median 95% range Median 95% range
Guinea pigs 14.25 1.23-8.78x103 203.23 11.94-1.10x105
Humans 0.23 6.82x10-5-0.71 0.18 1.05x10-5-10.52
η ρ
Median 95% range Median 95% range
Guinea pigs 1.34 0.0016-1.82x104 24.51 0.31-1.00x105
Humans 0.88 8.32x10-3-2.9x104 6.88 0.23-6.79x103
α - shape parameter of the infection beta-Poisson function.
β - scale parameter of the infection beta-Poisson function.
η - shape parameter of the illness beta-Poisson function.
ρ - scale parameter of the illness beta-Poisson function.
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symptoms of acute illness and that fraction may again
depend on the dose [13]. To account for a dose dependent
probability of symptoms we have used the conditional ill-
ness model proposed by Teunis et al. [13].
Pill inf cV η;ρÞ¼1− 1þηcVð Þ−ρjðj
With parameters (η,ρ) respectively describing the scale
and shape of the conditional illness model [13]. The dose
response data consist of groups of subjects (N) exposed to
different doses resulting in numbers infected (K) or symp-
tomatic (S), leading to a binomial likelihood
ℓ α; βð Þ ¼ PKinf 1−P infð ÞN−K
ℓ η; ρð Þ ¼ PSill 1−Pillð ÞK−S
where the probability of infection (Pinf ) depends on the
dose. The parameters for infectivity (α, β) were trans-
formed to improve convergence (see Teunis et al. [14]) andTable 3 Predicted number of outcomes for the data by expos
symptomatic (SP)
Tigertt guinea pig Tigert
Egg slurry E IP SP Egg slurry E
10-6 29 0.28 (0.12-0.73) 0.2 (0.001-0.69) 10-6 2 0.13 (0
10-5 26 2.37 (1.02-5.71) 2.13 (0.06-5.59) 10-5 5 2.09 (0
10-4 24 14.4 (7.85-20.65) 13.85 (3.35-20.61) 10-4.5 3 2.03 (0
10-3 27 26.96 (25.56-27) 26.91 (22.63-27) 10-4 8 6.26 (4
10-2 28 28 (27.92-28) 28 (26.83-28) 10-3 5 4.39 (3
10-1 24 24 (24–24) 24 (23.50-24) 10-2 4 3.71 (3
10-1 2 1.91 (1
Egg slurry - dilutions of 1 milliliter of infected egg slurry with milliliters of sterile wa
Bacteria - a Poisson process exposure number of bacteria.
E - number of exposed per exposure group.
IP - model predicted number of infected individuals per exposure group.
SP - model predicted number of symptomatic per exposure group.for illness (η, ρ) parameters were log normal distributions,
Additional file 1: code S1.
A useful measure for infectivity is the 50% infectious
dose (InfD50). This is the dose where 50% of the ex-
posed are expected to become infected based upon the
dose response relationship. Also, the 50% illness dose
(IllD50) where an estimated 50% of the exposed subjects
develop acute Q fever symptoms is useful. In addition, the
ratio of asymptomatic cases to a single symptomatic case,
which is used to estimate the total number of infected
from notified cases, can indicate differences in attack rates
within populations of different exposures. Using outbreak
data one could calculate backward from attack rates within
a population to make estimates about exposure.
Simultaneous estimation of parameters for the dose re-
sponse relations and the dilution factor relating the doses
of Tigertt et al. and Russell-Lodrigue et al. is most conveni-
ently done in a Bayesian framework by obtaining the joint
posterior probability of parameters from the combined
data sets and optimizing by means of Markov chain Monte
Carlo (MCMC). A graphical representation (DAG: directed
acyclic graph) of the model structure and dependencies,
see Additional file 1.
The model was implemented in JAGS (v3.2.0) and run
using rjags (v3-5) in R (v2.15.1).Results
The model was run for 5×107 iterations with a burnin of
1×106 and thinning of 5×104 iterations respectively; con-
vergence was checked (Gelman test, CODA [15]). Par-
ameter estimates for the model are briefly summarized
(Table 2) and predicted outcomes by the model are
reported (Table 3). Dose response relations for guinea pigs,
based on joint data from the Tigertt and Russell-Lodrigue
studies, were steep, indicating little heterogeneity in infect-
ivity (Figure 1a and b). Both guinea pig and human doseure group (E), predicted infected (IP), and predicted
t human Russell-Lodrigue guinea pig
IP SP Bacteria E IP SP
.03-0.42) 0.04 (0–0.27) 2 x 101 3 2.14 (0.92-2.79) 2.05 (0.80-2.73)
.61-4.02) 1.12 (0.16-3.39) 2 x 102 3 2.99 (2.75-3.00) 2.99 (2.56-3.00)
.87-2.77) 1.43 (0.44-2.57) 2 x 103 3 3 (2.99-3.00) 3 (2.89-3.00)
.09-7.57) 5.50 (2.97-7.12) 2 x 104 3 3.00 (3.00-3.00) 3.00 (2.95-3.00)
.80-4.80) 4.30 (3.67-4.74) 2 x 105 3 3.00 (3.00-3.00) 3.00 (2.98-3.00)
.23-3.95) 3.69 (3.13-3.94) 2 x 106 3 3.00 (3.00-3.00) 3.00 (2.99-3.00)
.63-1.99) 1.91 (1.61-1.99)
ter.
Figure 1 Dose response relations for C. burnetii. Median probability and 95% range as a function of dose: infection in guinea pigs (a),
symptoms of acute illness in guinea pigs (b), and infection (c) and acute illness symptoms (d) in humans.
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illness at low doses (Figure 1c and d); at high doses a
small fraction of humans appear to be protected against
infection, as indicated by the slow increase of the infec-
tion (and illness) probabilities with doses above a count
of 1000 live particles, which is similar to colony forming
units for other pathogens. The median probability of in-
fection from a single bacterium in humans is 0.44 (95%
CI 0.044-0.59) and the median probability of illness 0.12
(95%CI 0.0006-0.55) (Table 4). In guinea pigs the median
probability of infection is 0.06 (95%CI 0.016-0.14) and
the median probability of illness 0.04 (95%CI 0.0003-0.13).
The median dilution factor for the Tigertt study challenge
doses, representing the concentration difference betweenTable 4 Estimated Poisson dose for 50% probability of
infection and for 50% probability of acute illness
InfD50 IllD50
Median 95% range Median 95% range
Guinea pigs 10.69 5.04-38.42 11.79 5.26-44.13
Humans 1.54 0.75-38.69 4.68 0.87-51.00
InfD50 - the Poisson dose for 50% probability of infection.
IllD50 - the Poisson dose for 50% probability of illness.the two units of the study, is 142000 milliliters water to
one milliliter infected egg slurry (95% CI 47874–1075165)
(Figure 2); a single infectious particle in the Russell-
Lodrigue study is estimated to be equivalent to the same as
1 milliliter infected egg slurry homogenously mixed with
142 liters of water.
The variability in the infection risk from a single par-
ticle, as described by its (beta) distribution, is shown in
Figure 3.
Plotting the distribution of the InfD50 and IllD50
estimates from the data provides additional informa-
tion about the uncertainty of dose response relationship.
The guinea pigs have a less heterogeneous response
than humans, as shown in the narrow distributions of
InfD50 and IllD50 (Figure 4 - hatched lines). Estimates of
human data InfD50 and IllD50 show wide ranges, indi-
cating that risk of infection and illness may be more vari-
able (Figure 4 – solid lines).
The ratio of the human infected to ill ratio indicating
number of asymptomatic infections to symptomatic in-
fections decreases as the probability of illness increases
(Figure 5). As the dose increases the probability of in-
fection increases as does the probability of developing
illness.
Figure 2 Estimated concentration of C. burnetii in the inoculum
used in the human challenge study. Estimated posterior
probability density.
Brooke et al. BMC Infectious Diseases 2013, 13:488 Page 5 of 8
http://www.biomedcentral.com/1471-2334/13/488An overview of the parameters, their prior distribu-
tions, the model parameter estimations and model code
provides information about the model structure and the
Bayesian framework (Additional file 1).
Discussion and conclusions
To our knowledge this is the first human dose–response
model for C. burnetii that quantifies the exposure-outcome
relationship. Per single bacterium the median probability
of infection in humans is 0.44 (95%CI 0.044-0.59) and for
illness 0.12 (95%CI 0.0006-0.55), variability in the credible
intervals is observed in the probability density of infection
of a single bacteria, Figure 3. Humans appear more sus-
ceptible than guinea pigs to infection with C. burnetii
however with greater uncertainty. The cause may be the
specially bred Hartley guinea pigs, used both in Tigertt’s
and Russell-Lodrigue’s research, that are bred to reduce
genetic heterogeneity and therefore similar in their re-
sponse. In humans the InfD50 and the IllD50 are more
disperse than in guinea pigs indicating that there areFigure 3 Distribution of the probability of infection per single infectiou
guinea pigs (a) and in human volunteers (b). Median and 95% range of posteother (unknown) host factors that are affecting the dose
response relation.
In many published papers the proportion of infected
individuals developing illness is reported to be 40% [16].
Our model shows that the proportion of symptomatic
infections may vary with the exposure dose. Data from the
Dutch outbreaks report different proportions of asymp-
tomatic infections, which may be due to different exposure
levels [2,17]. In outbreaks with a well defined point source
[3,18] the distance from the outbreak source is negatively
correlated with the symptomatic (attack) rate. This may be
partly due to the dispersion of the aerosol over a larger
area leading to lower exposure levels at increasing distance
from the source. At lower doses the risk of infection de-
creases but the fraction of those infected who become ill
also decreases and thus the number of cases are expected
to drop even more rapidly with distance from the source.
Failing to take into account the increase in proportion of
asymptomatic cases as the exposure decreases may lead to
underestimation of the total number of individuals infected
in an outbreak.
At a low average dose of 0.1, as may be associated with
an exposure outside of a clinical setting, the median risk
of becoming ill is 0.006 (95%CI 0.00003-0.08) while the
median probability of infection is 0.06 (95%CI 0.005-
0.09). As a consequence, when spatial and temporal
clustering of cases is found, exposure to high numbers
of bacteria may be presumed: such recognizable clusters
of cases indicate severe exposure. However, when low
numbers of the pathogen are released, exposed subjects
may still be infected (due to their high susceptibility) but
far fewer of those infected develop acute symptoms.
Therefore, such low-level (endemic) infections tend to
cause isolated cases: the absence of clustering makes de-
tection of the source difficult. The demographics of an
exposed population are also important as men appear
to be symptomatic more frequently than women [19]
while infection appears gender independent [17]. Also,s particle. Characterization of susceptibility to infection with C. burnetii in
rior probability density.
Figure 4 Estimated dose where probability of infection is 50%
and probability of acute respiratory symptoms is 50%. Guinea
pigs infection hatched black curve, human infection solid black
curve, guinea pigs illness hatched red curve, humans illness solid
red curve.
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peaking around 60 years of age [19]. Whether these dif-
ferences arise from exposure differences or physiological
differences would need further investigation to validate
the use of this dose response relationship for exposure
quantification. However, once this has been incorporated
into the dose response relationship one could estimate
exposure from infection attack rates of infection and ill-
ness. One of the first outbreaks in the Netherlands with
a documented point source outbreak with a high attack
rate (17.59% of population acutely infected) may be used
to calculate crude estimates of exposure [18]. According
to this estimate, exposure is low, median 0.30 bacteria
(95%CI 0.21-5.67). Note that this means that on aver-
age one in three individuals was exposed to a single
bacterium.
A recent review of animal models for infectivity of Q
fever concluded that to estimate human infectivity patho-
gen aerosol challenge data was required [20]. AnimalFigure 5 Estimated ratio infected cases to symptomatic cases.studies are not appropriate for studying human infectiv-
ity as the animal hosts used are frequently immuno-
deficient and the infection pathway is frequently not
representative of natural infection. One study used three
different mouse strains injected intraperitoneally and re-
port a LD50 (50% lethal dose) of 2302 organisms [21].
The authors suggest that severe combined immunodefi-
cient (SCID) mice would be a good model for chronic Q
fever as immunodeficiency is a risk factor for chronic Q
fever in humans. Our results illustrate that immune
competent humans inoculated “naturally”, via aerosol,
are much more susceptible to C. burnetii infection than
these immune deficient mice inoculated intraperitoneally
(presumably bypassing respiratory barriers to infection).
Use of animals as surrogate hosts for dose response as-
sessment in humans can be misleading, as there is little
quantitative knowledge of how to translate susceptibility
across host species and/or inoculation routes. In a study
on the dose response relation for E. coli O157:H7 com-
paring an animal challenge model to human response
data, a strikingly similar pattern was found: human sus-
ceptibility was much higher than the estimate from the
animal model [22]. The paper of Tigertt et al. [6] can be
considered a model study for how to perform and inter-
pret animal dose response data by reporting a joint study
in humans and animals, using the same inoculum. See
also DuMouchel and Harris [23] for a proposed approach
to analyze such combined data.
The guinea pig challenge experiments of Tigertt et al.
and Russell-Lodrigue et al. have many similarities but
the two studies do use different strains of C. burnetii:
AD strain of C. burnetii (isolated from milk in California)
and the Nine Mile phase 1 (RSA 493) respectively. Our ti-
tration of the suspension used by Tigertt et al. is based on
the assumption that the two strains are equally infectious
in guinea pigs. Other studies have attempted to identify if
there are differences in infectivity between strains but with
doses of many orders of magnitude higher, immune defi-
cient animal hosts, lipoprotein antigens instead of bacteria,
and/or mortality instead of infection as an outcome
[21,24,25]. There are no studies of strain infectivity in
guinea pigs or with aerosol challenge models. Another as-
sumption is that the serological tests used, complement
fixation (CF) in the Tigertt et al. study and enzyme-linked
immunosorbent assay (ELISA) in the Russell-Lodrigue
et al. study, are similar in their sensitivity and specificity. A
study comparing the two tests show they have comparable
sensitivity (100%/100% vs 100%/67% for phase II and phase
I respectively) and specificity (100%/100% vs 95%/95%) for
IgG [26]. There is no information about clustering or ag-
gregation in the studies but the beta distribution provides
information regarding the variation in infectivity of indi-
vidual infectious units, Figure 3, part of which may reflect
variation in the numbers of infectious bacteria per
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adds heterogeneity and would make the dose response
relationship less steep. Unpublished observations of nat-
ural settings are usually close to detection limits of real-
time polymerase chain reaction (qPCR), which suggests
that when present the bacteria are more likely single
units than clumps of multiple bacteria. However, sensi-
tivity and specificity of the used assays may affect
these results and their interpretations.
A methodological issue with the study, compared to a
clinical trial, is the low number of cases in the different
challenge dose groups. However, human challenge stud-
ies are rarely very large and despite the small group
numbers the dose response relation is very well defined.
Additions to the framework, including additional data
sources from natural experiments, may allow further re-
finement of the dose response relationship though these
have their own issues regarding exposure quantification
and exposure time. A second methodological issue is the
assumption that none of the challenged subjects have
been previously infected. The United States’s national Q
fever seroprevalence was recently estimated at 3.1% [27]
and though subjects may seroconvert, antibody levels
measured before being challenged may have been below
detection level. If an immune subject were included in
the experiment, an expected outcome might be to ob-
serve a seroconversion but not develop illness. In the
study with human subjects, two cases were observed to
seroconvert without illness. To test what the effects of
missing such a case would be, a sensitivity analysis was
performed by increasing the positive responses in the chal-
lenge groups (infection and illness) by one (scenario 1) or
by two individuals (scenario 2). Resulting estimates were
similar, unless the scenario led to groups with 100% infec-
tion. The model was also run without any data in the
model and the posterior distributions of the parameters
did not change significantly (Additional file 1: Table S1).
The experimental study of the illness dose response in-
cludes mild cases as well as severe cases, which are more
likely to be identified and notified. In the Netherlands, a
watchful waiting period of two weeks, the average dur-
ation of acute Q fever, is frequently employed for febrile
illnesses. In the Tigertt study the duration of symptoms
and the length of the incubation period of challenged
subjects were dose dependent. This will affect the num-
ber of notified cases as individuals with a low dose and
mild illness will be resolved within the watchful waiting
period. The dose response relationship for humans indi-
cates different infection rates for different doses; high in-
fectivity is observed at low bacterial levels while higher
doses increase the probability of infection illness. The
more than 3500 notified cases may only represent a small
proportion of the number infected in the Netherlands and
estimates of 40,000 infected may not be exaggerated.Additional file
Additional file 1: Figure S1. Simplified directed acyclic graph of the
model without priors. Table S1. Prior distributions (mean, sd) in the Bayesian
framework, posterior distributions and posterior distributions of the model
without data. Code S1 JAGS model representing the Bayesian framework.
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